Author:
Andreoni Massimo,Di Perri Giovanni,Persico Marcello,Marcellusi Andrea,Ethgen Olivier,Sanchez Gonzalez Yuri,Bondin Mark,Zhang Zhenzhen,De Michina Antonella,Merolla Rocco Cosimo Damiano,Craxì Antonio
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical)
Reference31 articles.
1. World Health Organization. Global hepatitis report. 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf. Accessed 1 Nov 2020.
2. Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C. J Hepatol. 2018;69(2):461–511. https://doi.org/10.1016/j.jhep.2018.03.026.
3. Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med. 2019;35(3):161–70. https://doi.org/10.1159/000500963.
4. AbbVie. Maviret (glecaprevir/pibrentasvir) summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_en.pdf. Accessed Mar 2020.
5. AbbVie. Mavyret (glecaprevir/pibrentasvir) US prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s008lbl.pdf. Accessed Mar 2020.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献